FCFanny Collaud

Fanny Collaud

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fanny Collaud has a total of 225 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Single-vector AAV delivery of En-ISPmu1 and donor DNA for in vivo targeted genome integration

    by Alessio Conci, Ilaria Bonuzzi, Matteo Ciciani, Federica Esposito, Pasquale Piccolo, Fanny Collaud, Giuseppe Ronzitti, Alberto Auricchio, Nicola Segata, Anna Cereseto

    TnpBs are compact RNA-guided nucleases ideally suited for in vivo delivery. By screening novel TnpBs identified from large metagenomic datasets, ISPmu1 was discovered and its protein and ωRNA were engineered to generate En-ISPmu1, which achieved editing efficiencies exceeding 65% across 12 human loci. Owing to its compact size, En-ISPmu1 was delivered together with a donor DNA in a single AAV vector, yielding up to 12.7% targeted integration in mouse liver. These findings establish En-ISPmu1 as a promising versatile platform for in vivo therapeutic genome editing applications.

  • Open Access

    Editorial: Gene therapy and genome editing for metabolic liver disorders

    by Fanny Collaud, Giulia Bortolussi

    Metabolic liver disorders are a diverse group of conditions that affect the ability of the liver to process and metabolize nutrients, which can lead to severe complications if left untreated, such as liver damage or even liver failure. These disorders are often the result of genetic mutations affecting enzymes, transporters, structural proteins, or organelles that are essential for metabolic processes. Metabolic liver disorders pose significant health challenges and have historically been difficult to treat. Traditional treatments involve dietary management and enzyme replacement therapies, which can be burdensome and only partially effective. For a long time, liver transplantation was the only curative option for these inherited disorders, requiring lifelong immune suppression. But today, a medical revolution is underway.Recent breakthroughs in gene therapy and genome editing technologies offer promising avenues for effective and long-lasting treatments. By correcting the underlying genetic defects, these cuttingedge approaches in molecular medicine can restore normal metabolic function and significantly improve the quality of life for affected individuals. What was considered revolutionary just a few years ago, is now being used successfully in humans solving previously very unfavorable conditions. Despite undeniable successes and continuous development of novel approaches, challenges remain to improve safety and efficacy of gene therapies, such as pre-existing humoral response, long-term transgene persistence, potential genotoxicity, or high vector dose-related acute inflammatory responses.Ongoing research focuses on improving the precision and safety of these therapies. Innovations include the development of novel vectors for efficient gene delivery, high-fidelity endonucleases to minimize off-target effects, and strategies to modulate the immune response to allow for repeated administration. Additionally, there is an increased possibility for translating these therapies into clinical practice due to progresses in vector design, manufacturing and regulatory paths.The research presented in this topic highlights the transformative potential of these technologies.The review article proposed by Palacio and colleagues "Revolutionizing In vivo Therapy with CRISPR/Cas Genome Editing: Breakthroughs, Opportunities and Challenges", delves into the revolutionary impact of CRISPR/Cas9 technology on in vivo therapy. It discusses the breakthroughs achieved in precise genome editing, the opportunities for treating a wide range of genetic disorders, and their challenges, such as off-target effects and delivery efficiency.Diverse strategies to improve adeno-associated virus (AAV) vectors are discussed by Shitika et al. in "AAV-based Vector Improvements Unrelated to Capsid Protein Modification". This research addresses the advancements in AAV-based vector technology, focusing on improvements that do not involve capsid protein modification but modifying the structures determining the viral life cycle. These innovations enhance AAV production, transduction efficiency, and transgene expression in tissues of interest, making gene therapy more effective and reducing the risk of side effects.Severe metabolic liver disorders and unmet medical needs that are glycogen storage diseases type I (GSDI) and familial hypercholesterolemia (FH), are examples of conditions for which gene therapy and gene editing offer promising therapeutic options for the future. GSDI are characterized by the accumulation of glycogen in the liver and kidneys due to a deficient glucose-6-phosphatase enzyme activity, leading to impaired glucose release and various metabolic complications. Several gene therapy strategies have been investigated to cure GSDI and they are reviewed here by Chou & Mansfield in the article "Gene Therapy and Genome Editing for Type I Glycogen Storage Diseases". Notably, authors highlight the progress made in AAV-mediated gene augmentation approaches and their current potential to provide a permanent cure for these diseases. They also propose a brief overview of the most recent research using CRISPR/Cas9-based in vivo genome editing technology developed for these conditions.FH is a genetic disorder that affects how the body processes cholesterol, characterized by very high levels of low-density lipoprotein (LDL) cholesterol. This can lead to an increased risk of cardiovascular disease and early heart attacks if not managed properly. Current treatments focus on lowering LDL cholesterol levels, thanks to medications (statins, PCSK9 inhibitors), diet rich in fruits and vegetables, or lipoprotein apheresis. Within the article "Gene Transfer and Genome Editing for Familial Hypercholesterolemia", Canepari & Cantore explore the use of gene transfer and genome editing to correct this disease, discussing their advantages and weaknesses, and outline the strategies that could become the drugs of tomorrow.Overall, the researches presented in this topic underscores the significant strides made in gene therapy and genome editing for metabolic liver disorders. The collective efforts of the scientific community in advancing these therapies not only pave the way for curing metabolic liver disorders but also set the stage for tackling a broader range of genetic diseases. The journey ahead is dense of opportunities and challenges, but the potential benefits for patients are countless, making this an exciting and pivotal area of research.

  • Open Access

    Synergism of dual AAV gene therapy and rapamycin rescues GSDIII phenotype in muscle and liver

    by Louisa Jauze, Mallaury Vie, Quentin Miagoux, Lucille Rossiaud, Patrice Vidal, Valle Montalvo-Romeral, Hanadi Saliba, Margot Jarrige, Helene Polveche, Justine Nozi, et al.

    Glycogen storage disease type III (GSDIII) is a rare metabolic disorder due to glycogen debranching enzyme (GDE) deficiency. Reduced GDE activity leads to pathological glycogen accumulation responsible for impaired hepatic metabolism and muscle weakness. To date, there is no curative treatment for GSDIII. We previously reported that 2 distinct dual AAV vectors encoding for GDE were needed to correct liver and muscle in a GSDIII mouse model. Here, we evaluated the efficacy of rapamycin in combination with AAV gene therapy. Simultaneous treatment with rapamycin and a potentially novel dual AAV vector expressing GDE in the liver and muscle resulted in a synergic effect demonstrated at biochemical and functional levels. Transcriptomic analysis confirmed synergy and suggested a putative mechanism based on the correction of lysosomal impairment. In GSDIII mice livers, dual AAV gene therapy combined with rapamycin reduced the effect of the immune response to AAV observed in this disease model. These data provide proof of concept of an approach exploiting the combination of gene therapy and rapamycin to improve efficacy and safety and to support clinical translation.


  • Open Access

    Chronically elevated FGF23 drives sustained renal ERK signaling and inflammatory transcriptional programs mitigated by cFGF23 gene therapy

    by Adrian Salas-Bastos, Claire Bardet, Klaudia Kopper, Louisa Jauze, Fanny Collaud, Amandine Francois, Matthias B. Moor, Gaozhi Chen, Moosa Mohammadi, Christian Stockmann, et al.

    Fibroblast growth factor 23 (FGF23) levels are highly elevated in patients with chronic kidney disease (CKD); however, whether it serves merely as a biomarker or actively contributes to kidney inflammation remains unclear. Full-length FGF23 is cleaved into C-terminal FGF23 (cFGF23), which acts as a natural antagonist of FGF23 by inhibiting its binding to the FGF receptor (FGFR) and the co-receptor Klotho. Here, we show that chronically elevated FGF23 levels in a mouse model Hyp-Duk cause sustained-ERK signaling and an inflammatory and immune responses in the kidney. cFGF23, delivered via adeno-associated virus (AAV) gene therapy, successfully mitigated renal sustained-ERK signaling and inflammatory and immune responses in Hyp-Duk mice. On the other hand, acute physiological FGF23 levels in vitro elicited transient-ERK signaling with the expression of canonical early-ERK targets ( EGR1, JUNB, FOSB ). Consistent with in vivo findings, prolonged pathological FGF23 treatment in-vitro revealed sustained-ERK signaling with upregulation of late-ERK targets ( ETV4/5, SPRED1/2, SPRY2/4 ) and unique inflammatory and immune gene signatures. These effects were significantly mitigated by FGFR and ERK inhibitors, as well as by recombinant cFGF23 treatment. In summary, chronically high levels of FGF23 induce kidney inflammation through the FGFR-Klotho complex and sustained-ERK activation, which are successfully mitigated by cFGF23 gene therapy. TRANSLATIONAL STATEMENT: Chronically elevated circulating levels of Fibroblast Growth Factor 23 (FGF23) are strongly associated with inflammation and adverse outcomes in chronic kidney disease, but the underlying mechanisms remain poorly understood. Our study identifies sustained activation of the ERK signaling pathway as a key mechanism by which chronic FGF23 elevation induces inflammatory transcriptional programs in the kidney. Importantly, gene therapy using the C-terminal fragment of FGF23 (cFGF23) mitigates these effects, highlighting a potential therapeutic strategy to counteract the excessive FGF23 signaling.


  • Open Access

    Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates

    by Helena Costa-Verdera, Fanny Collaud, Christopher R. Riling, Pauline Sellier, Jayme M. L. Nordin, G. Michael Preston, Umut Cagin, Julien Fabregue, Simon Barral, Maryse Moya-Nilges, et al.

    Pompe disease (PD) is a severe neuromuscular disorder caused by deficiency of the lysosomal enzyme acid alpha-glucosidase (GAA). PD is currently treated with enzyme replacement therapy (ERT) with intravenous infusions of recombinant human GAA (rhGAA). Although the introduction of ERT represents a breakthrough in the management of PD, the approach suffers from several shortcomings. Here, we developed a mouse model of PD to compare the efficacy of hepatic gene transfer with adeno-associated virus (AAV) vectors expressing secretable GAA with long-term ERT. Liver expression of GAA results in enhanced pharmacokinetics and uptake of the enzyme in peripheral tissues compared to ERT. Combination of gene transfer with pharmacological chaperones boosts GAA bioavailability, resulting in improved rescue of the PD phenotype. Scale-up of hepatic gene transfer to non-human primates also successfully results in enzyme secretion in blood and uptake in key target tissues, supporting the ongoing clinical translation of the approach.


  • Top Cited Papers

    IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies

    by Christian Leborgne, Elena Barbon, Jeffrey M. Alexander, Hayley Hanby, Sandrine Delignat, Daniel M. Cohen, Fanny Collaud, Saghana Muraleetharan, Dan Lupo, Joseph Silverberg, et al.

    Neutralizing antibodies to adeno-associated virus (AAV) vectors are highly prevalent in humans1,2, and block liver transduction3,4,5 and vector readministration6; thus, they represent a major limitation to in vivo gene therapy. Strategies aimed at overcoming anti-AAV antibodies are being studied7, which often involve immunosuppression and are not efficient in removing pre-existing antibodies. Imlifidase (IdeS) is an endopeptidase able to degrade circulating IgG that is currently being tested in transplant patients8. Here, we studied if IdeS could eliminate anti-AAV antibodies in the context of gene therapy. We showed efficient cleavage of pooled human IgG (intravenous Ig) in vitro upon endopeptidase treatment. In mice passively immunized with intravenous Ig, IdeS administration decreased anti-AAV antibodies and enabled efficient liver gene transfer. The approach was scaled up to nonhuman primates, a natural host for wild-type AAV. IdeS treatment before AAV vector infusion was safe and resulted in enhanced liver transduction, even in the setting of vector readministration. Finally, IdeS reduced anti-AAV antibody levels from human plasma samples in vitro, including plasma from prospective gene therapy trial participants. These results provide a potential solution to overcome pre-existing antibodies to AAV-based gene therapy.


  • Open Access

    Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors

    by Elena Barbon, Gabriel Ayme, Amel Mohamadi, Jean‐François Ottavi, Charlotte Kawecki, Caterina Casari, Sebastien Verhenne, Solenne Marmier, Laetitia van Wittenberghe, Severine Charles, et al.

    Novel therapies for hemophilia, including non‐factor replacement and in vivo gene therapy, are showing promising results in the clinic, including for patients having a history of inhibitor development. Here, we propose a novel therapeutic approach for hemophilia based on llama‐derived single‐domain antibody fragments (sdAbs) able to restore hemostasis by inhibiting the antithrombin (AT) anticoagulant pathway. We demonstrated that sdAbs engineered in multivalent conformations were able to block efficiently AT activity in vitro , restoring the thrombin generation potential in FVIII‐deficient plasma. When delivered as a protein to hemophilia A mice, a selected bi‐paratopic sdAb significantly reduced the blood loss in a model of acute bleeding injury. We then packaged this sdAb in a hepatotropic AAV8 vector and tested its safety and efficacy profile in hemophilic mouse models. We show that the long‐term expression of the bi‐paratopic sdAb in the liver is safe and poorly immunogenic, and results in sustained correction of the bleeding phenotype in hemophilia A and B mice, even in the presence of inhibitory antibodies to the therapeutic clotting factor.


  • Open Access

    Capsid-specific removal of circulating antibodies to adeno-associated virus vectors

    by Berangere Bertin, Philippe Veron, Christian Leborgne, Jack-Yves Deschamps, Sophie Moullec, Yves Fromes, Fanny Collaud, Sylvie Boutin, Virginie Latournerie, Laetitia van Wittenberghe, et al.

    Neutralizing antibodies directed against adeno-associated virus (AAV) are commonly found in humans. In seropositive subjects, vector administration is not feasible as antibodies neutralize AAV vectors even at low titers. Consequently, a relatively large proportion of humans is excluded from enrollment in clinical trials and, similarly, vector redosing is not feasible because of development of high-titer antibodies following AAV vector administration. Plasmapheresis has been proposed as strategy to remove anti-AAV antibodies from the bloodstream. Although safe and relatively effective, the technology has some limitations mainly related to the nonspecific removal of all circulating IgG. Here we developed an AAV-specific plasmapheresis column which was shown to efficiently and selectively deplete anti-AAV antibodies without depleting the total immunoglobulin pool from plasma. We showed the nearly complete removal of anti-AAV antibodies from high titer purified human IgG pools and plasma samples, decreasing titers to levels that allow AAV vector administration in mice. These results provide proof-of-concept of a method for the AAV-specific depletion of neutralizing antibodies in the setting of in vivo gene transfer.


  • Open Access

    Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle

    by Jérôme Poupiot, Helena Costa Verdera, Romain Hardet, Pasqualina Colella, Fanny Collaud, Laurent Bartolo, Jean Davoust, Peggy Sanatine, Federico Mingozzi, Isabelle Richard, et al.


  • Open Access

    Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler–Najjar Syndrome

    by Sem J. Aronson, Philippe Veron, Fanny Collaud, Aurélie Hubert, Virginie Delahais, Géraldine Honnet, Robert J. de Knegt, Norman Junge, Ulrich Baumann, Angelo Di Giorgio, et al.

    Adeno-associated virus (AAV) vector-mediated gene therapy is currently evaluated as a potential treatment for Crigler–Najjar syndrome (CN) (NCT03466463). Pre-existing immunity to AAV is known to hinder gene transfer efficacy, restricting enrollment of seropositive subjects in ongoing clinical trials. We assessed the prevalence of anti-AAV serotype 8 (AAV8) neutralizing antibodies (NAbs) in subjects affected by CN and investigated the impact of low NAb titers (in vivo passive immunization model. A total of 49 subjects with a confirmed molecular diagnosis of CN were included in an international multicenter study (NCT02302690). Pre-existing NAbs against AAV8 were detected in 30.6% (15/49) of screened patients and, in the majority of positive cases, cross-reactivity to AAV2 and AAV5 was detected. To investigate the impact of low NAbs on AAV vector-mediated liver transduction efficiency, adult wild-type C57BL/6 mice were passively immunized with pooled human donor-derived immunoglobulins to achieve titers of up to 1:3.16. After immunization, animals were injected with different AAV8 vector preparations. Hepatic vector gene copy number was unaffected by low anti-AAV8 NAb titers when column-purified AAV vector batches containing both full and empty capsids were used. In summary, although pre-existing anti-AAV8 immunity can be found in about a third of subjects affected by CN, low anti-AAV8 NAb titers are less likely to affect liver transduction efficiency when using AAV vector preparations manufactured to contain both full and empty capsids. These findings have implications for the design of liver gene transfer clinical trials and for the definition of inclusion criteria related to seropositivity of potential participants.